Compare drug alternatives
Takhzyro® Alternatives
Takhzyro®(lanadelumab-flyo) | Berinert®(C1 esterase inhibitor (human)) |
---|---|
Prescription Only | Prescription Only |
Dosage & Administration | |
Administration | |
Subcutaneous. Learn more. | Intravenous. Learn more. |
Dosing | |
Adult and pediatric patients 12 years of age and older: administer 300 mg every 2 weeks. 6 to less than 12 years of age: administer 150 mg every 2 weeks. Pediatric patients 2 to less than 6 years of age: administer 150 mg every 4 weeks.. Learn more. | Administer 20 International Units per kg body weight.. Learn more. |
Latin Shorthand | |
Adult and pediatric patients (≥12 years): 300 mg every 2 weeks. Patients aged 6 to <12 years: 150 mg every 2 weeks. Patients aged 2 to <6 years: 150 mg every 4 weeks.. Learn more. | Administer 20 IU/kg BW.. Learn more. |
Financial Assistance | |
Out-Of-Pocket Costs With Copay Card | |
$0. Learn more. | |
Annual Cap | |
Assistance Expiration | |
Generics | |
No lower-cost generic available | No lower-cost generic available |
Physician Advisory | |
Adverse Reactions | |
The most common adverse reactions (≥10%) are injection site
reactions, upper respiratory infections, headache, rash, dizziness,
diarrhea, and myalgia.. Learn more. | The most serious adverse reaction reported in subjects who received BERINERT was
an increase in the severity of pain associated with HAE.
•The most common adverse reaction reported in greater than 4% of the subjects
and greater than placebo among subjects who received BERINERT in the placebo-controlled clinical trial was dysgeusia.. Learn more. |
Mechanism of Actions (MoA) | |
Drugs used in Hereditary Angioedema. Learn more. | Drugs used in Hereditary Angioedema. Learn more. |
Special Populations | |
Popular Alternatives
- Takhzyro® vs Orladeyo®
- Takhzyro® vs Cinryze®
- Takhzyro® vs Haegarda®
- Takhzyro® vs Kalbitor®
- Takhzyro® vs Firazyr®
- Takhzyro® vs Sajazir®
- Takhzyro® vs Ruconest®